AbbVie Inc., a leading pharmaceutical company, recently revealed its yearly earnings outlook in its fourth-quarter earnings report.
Without considering certain financial items, the company expects its annual earnings per share to range from $11.05 to $11.25. This prediction factors in a $0.32 per share impact resulting from the proposed acquisitions of ImmunoGen and Cerevel Therapeutics. These deals are projected to finalize around mid-2024.
Based on a poll by Thomson Reuters, the average expectation from 27 analysts is for the company to earn $11.24 per share for the year, although this typically omits special items.
In 2023, the company reported an adjusted income per share of $11.11.
Furthermore, AbbVie reaffirmed its projected high single-digit compound annual growth rate for revenue through 2029.
